Skip to main content

Table 3 Univariate analysis of the predictors for failure in clinical resolution (CR)

From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

Variables With CRa n = 57 Without CRa n = 20 OR (95% CI) p
Demographic parameters
 Age, year 59.4 (18.9) 63.09 (16.3)   0.464
 Female gender 16 (28.1%) 9 (45.0%) 0.48 (0.17–1.37) 0.164
Comorbidities
 Hepatic dysfunction 2 (3.5%) 0 (0.0%) 0.73 (0.64–0.84) 1.000
 Renal insufficiency 6 (10.5%) 1 (5.0%) 2.24 (0.25–19.80) 0.669
 Chronic pulmonary disease 14 (24.6%) 7 (35.0%) 0.60 (0.20–1.82) 0.367
 Heart disease 11 (19.3%) 2 (10.0%) 2.15 (0.43–10.68) 0.495
 Diabetes mellitus 3 (5.3%) 1 (5.0%) 1.06 (0.10–10.77) 1.000
 Immune compromise 3 (5.3%) 2 (10.0%) 0.50 (0.08–3.23) 0.600
 Malignancy 5 (8.8%) 2 (10.0%) 0.86 (0.15–4.86) 1.000
 Hypoproteinemia 1 (1.8%) 1 (5.0%) 0.34 (0.20–5.69) 0.455
 Surgery 11 (19.3%) 5 (25.0%) 0.72 (0.22–2.34) 0.749
Clinical conditions
 CURB65 score, mean ± SD 2.4 (0.6) 1.9 (1.1)   0.006
 Mechanical ventilation 31 (64.6%) 17 (85.0%) 0.21 (0.06–0.80) 0.015
 Albumin 31.7 (5.7) 32.2 (4.0)   0.512
Microbiology
 Bacteremia 2 (3.5%) 5 (25.0%) 0.11 (0.02–0.62) 0.011
 Tigecycline resistance 33 (57.9%) 9 (45.0%) 1.68 (0.60–4.69) 0.319
 Airway eradication of MDRAB 21 (51.2%) 3 (18.8%) 4.55 (1.13–18.39) 0.026
Tigecycline treatment
 Duration, days 8.4 (3.7) 12.9 (6.4)   0.001
Combination therapy
 With sulbactam 49 (86.0%) 15 (75.0%) 2.04 (0.58–7.19) 0.304
 With carbapenems 3 (5.3%) 1 (5.0%) 1.06 (0.10–10.77) 1.000
 With amikacin 2 (3.6%) 1 (5.0%) 0.70 (0.06–8.21) 1.000
 With fluoroquinolones 4 (7.0%) 0 (0.0%) 0.73 (0.63–0.84) 0.568
Delayed tigecycline treatment 19 (33.3%) 2 (10.0%) 4.50 (0.86–13.31) 0.044
  1. Abbreviations: OR odd ratio, CI confidence interval, MDRAB multidrugresistik Acinetobacter baumannii
  2. aCategorical data are no.(%) of subject, continuous data are expressed as mean (standard deviation)